| 1.43 -0.1 (-6.54%) | 06-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.43  |
1-year : | 2.92 |
| Resists | First : | 2.08 |
Second : | 2.5 |
| Pivot price | 1.88 |
|||
| Supports | First : | 1.41 |
Second : | 1.18 |
| MAs | MA(5) : | 1.59 |
MA(20) : | 1.92 |
| MA(100) : | 3.86 |
MA(250) : | 2.44  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 5.3 |
D(3) : | 5.5 |
| RSI | RSI(14): 22.2 |
|||
| 52-week | High : | 8.19 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MYNZ ] has closed below the lower bollinger band by 2.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MYNZ ] is to continue within current trading range. It is unclear right now based on current values. 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.39 - 1.41 | 1.41 - 1.42 |
| Close: | 1.41 - 1.44 | 1.44 - 1.46 |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Thu, 05 Jun 2025
Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Wed, 21 May 2025
Mainz Biomed N.V. Secures $4 Million Through Securities Offering - TipRanks
Mon, 19 May 2025
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com
Tue, 01 Apr 2025
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Fri, 28 Mar 2025
Mainz Biomed stock hits 52-week low at $3.65 amid sharp annual decline - Investing.com
Mon, 02 Dec 2024
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.7e+006 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.771e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 307.2 % |
| Return on Equity (ttm) | -80.4 % |
| Qtrly Rev. Growth | 893990 % |
| Gross Profit (p.s.) | -42.26 |
| Sales Per Share | -1502.65 |
| EBITDA (p.s.) | 1.85445e+006 |
| Qtrly Earnings Growth | -22.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.16 |
| Dividend | 0 |
| Forward Dividend | 96180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|